Medication info
Zobatin Tablet 20 mg (Simvastatin)

Zobatin Tablet 20 mg (Simvastatin)

Prescription medicationTabletOral
Ingredient · strength
Simvastatin›20mg / 1 tablet
Manufacturer / importer
Jinyang Pharmaceutical Co., Ltd.
Appearance
Brownish yellow oval film-coated tablet
Packaging
(Domestic) 30 tablets/bottle, 100 tablets/bottle (Export) 30 tablets (10 tablets x 3 PTP)
Approval status
Active

MFDS item code 200401411 · Notified 2004.01.28 · Insurance code 650301130

Summary

Main use
Improvement of hyperlipidemia, improvement of familial hypercholesterolemia in children, and prevention of cardiovascular disease
Who takes it
Adults · Children
Adult dose
Patients receiving this medicine should follow a standard cholesterol-lowering diet before and during treatment. 1. Reduction of cardiovascular risk The recommended initial dose is 40 mg of simvastatin once daily. 2. Hyperlipidemia 1) Reduction of risk in patients with coronary heart disease and hypercholesterolemia, and hyperlipidemia The recommended usual initial dose is 20 mg of this medicine once daily in the evening. Patients with mild to moderate hypercholesterolemia may start with 10 mg of this medicine. A dose of 5 ~ 40 mg of this medicine once daily in the evening is recommended. Adjust the dose as appropriate according to the initial LDL cholesterol level before starting treatment, the treatment goal, and the patient's response to the medicine. Measure cholesterol levels 4 weeks after starting treatment and periodically thereafter, and adjust the dose. Reduce the dose if the cholesterol level falls below the target level. Due to the increased risk of myopathy, including rhabdomyolysis, use of the 80 mg dose of this medicine, particularly during the first year of treatment, is restricted to patients who have been taking 80 mg of this medicine for 12 months or longer without evidence of muscle toxicity (see 1. Warnings under Precautions for Use). 2) For recommended doses in patients receiving this medicine concomitantly with fibrates (excluding gemfibrozil and fenofibrate), amiodarone, verapamil, diltiazem, or amlodipine, and in specific patient groups (i.e., patients with homozygous familial hypercholesterolemia, older adults, and patients with renal impairment), see the information below (see 6. Interactions under Precautions for Use). (1) Administration to patients with homozygous familial hypercholesterolemia Based on the results of controlled clinical trials, patients with homozygous familial hypercholesterolemia should receive 40 mg of this medicine once daily in the evening. This medicine should be administered in combination with other lipid-lowering treatments (e.g., LDL apheresis), or when other lipid-lowering treatments are not available. (2) In older adults, a daily dose of 20 mg of this medicine may provide the maximum cholesterol-lowering effect. (3) Administration to patients receiving verapamil, diltiazem, or dronedarone When this medicine is administered concomitantly to patients receiving verapamil, diltiazem, or dronedarone, the dose of this medicine should not exceed 10 mg daily. (4) Administration to patients receiving amiodarone, amlodipine, or ranolazine When this medicine is administered concomitantly to patients receiving amiodarone, amlodipine, or ranolazine, the dose of this medicine should not exceed 20 mg daily. (5) Concomitant administration with other lipid-lowering agents This medicine is effective when administered alone or in combination with a bile acid sequestrant. When this medicine is administered concomitantly with a fibrate (excluding gemfibrozil (see 2. Patients Who Should Not Take This Medicine under Precautions for Use) and fenofibrate), the dose of this medicine should not exceed 10 mg daily. (6) Administration to patients with renal impairment Because this medicine is not excreted extensively by the kidneys, no dose adjustment is necessary in patients with mild to moderate renal impairment. However, in patients with severe renal impairment, treatment should be initiated at 5 mg daily and the patient should be monitored carefully.
Child dose
Pediatric patients with heterozygous familial hypercholesterolemia (10 ~ 17 years): The recommended initial dose is 10 mg of this medicine once daily in the evening. The recommended dose range is 10 ~ 40 mg daily, and the recommended maximum dose is 40 mg daily. Adjust the dose appropriately for each patient according to the recommended treatment goal. Allow an interval of 4 weeks or longer between dose adjustments.

Ingredients

Manufacturer
Jinyang Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of hyperlipidemia, improvement of familial hypercholesterolemia in children, and prevention of cardiovascular disease

  • Coronary heart disease
  • diabetes
  • peripheral vascular disease
  • stroke
  • hypercholesterolemia
  • dyslipidemia
  • abnormal beta-lipoproteinemia
  • hypertriglyceridemia
  • familial hypercholesterolemia
View approved original text

This medication is effective in reducing the risk of cardiovascular diseases. It lowers the risk of mortality from heart disease and events such as myocardial infarction and stroke in adult patients with a history of coronary heart disease, diabetes, peripheral vascular disease, or stroke. Additionally, it reduces the risk of complications after vascular surgeries. In hyperlipidemia patients, it decreases total cholesterol and bad LDL cholesterol levels while increasing good HDL cholesterol levels, thereby improving blood lipid concentrations. It is particularly used as an adjunctive treatment for familial hypercholesterolemia or mixed dyslipidemia and can be applied to children with familial hypercholesterolemia. This medication is used to maintain cardiovascular health and reduce the risk of cardiovascular diseases.

How to take

Adult dose

Patients receiving this medicine should follow a standard cholesterol-lowering diet before and during treatment. 1. Reduction of cardiovascular risk The recommended initial dose is 40 mg of simvastatin once daily. 2. Hyperlipidemia 1) Reduction of risk in patients with coronary heart disease and hypercholesterolemia, and hyperlipidemia The recommended usual initial dose is 20 mg of this medicine once daily in the evening. Patients with mild to moderate hypercholesterolemia may start with 10 mg of this medicine. A dose of 5 ~ 40 mg of this medicine once daily in the evening is recommended. Adjust the dose as appropriate according to the initial LDL cholesterol level before starting treatment, the treatment goal, and the patient's response to the medicine. Measure cholesterol levels 4 weeks after starting treatment and periodically thereafter, and adjust the dose. Reduce the dose if the cholesterol level falls below the target level. Due to the increased risk of myopathy, including rhabdomyolysis, use of the 80 mg dose of this medicine, particularly during the first year of treatment, is restricted to patients who have been taking 80 mg of this medicine for 12 months or longer without evidence of muscle toxicity (see 1. Warnings under Precautions for Use). 2) For recommended doses in patients receiving this medicine concomitantly with fibrates (excluding gemfibrozil and fenofibrate), amiodarone, verapamil, diltiazem, or amlodipine, and in specific patient groups (i.e., patients with homozygous familial hypercholesterolemia, older adults, and patients with renal impairment), see the information below (see 6. Interactions under Precautions for Use). (1) Administration to patients with homozygous familial hypercholesterolemia Based on the results of controlled clinical trials, patients with homozygous familial hypercholesterolemia should receive 40 mg of this medicine once daily in the evening. This medicine should be administered in combination with other lipid-lowering treatments (e.g., LDL apheresis), or when other lipid-lowering treatments are not available. (2) In older adults, a daily dose of 20 mg of this medicine may provide the maximum cholesterol-lowering effect. (3) Administration to patients receiving verapamil, diltiazem, or dronedarone When this medicine is administered concomitantly to patients receiving verapamil, diltiazem, or dronedarone, the dose of this medicine should not exceed 10 mg daily. (4) Administration to patients receiving amiodarone, amlodipine, or ranolazine When this medicine is administered concomitantly to patients receiving amiodarone, amlodipine, or ranolazine, the dose of this medicine should not exceed 20 mg daily. (5) Concomitant administration with other lipid-lowering agents This medicine is effective when administered alone or in combination with a bile acid sequestrant. When this medicine is administered concomitantly with a fibrate (excluding gemfibrozil (see 2. Patients Who Should Not Take This Medicine under Precautions for Use) and fenofibrate), the dose of this medicine should not exceed 10 mg daily. (6) Administration to patients with renal impairment Because this medicine is not excreted extensively by the kidneys, no dose adjustment is necessary in patients with mild to moderate renal impairment. However, in patients with severe renal impairment, treatment should be initiated at 5 mg daily and the patient should be monitored carefully.

Child dose

Pediatric patients with heterozygous familial hypercholesterolemia (10 ~ 17 years): The recommended initial dose is 10 mg of this medicine once daily in the evening. The recommended dose range is 10 ~ 40 mg daily, and the recommended maximum dose is 40 mg daily. Adjust the dose appropriately for each patient according to the recommended treatment goal. Allow an interval of 4 weeks or longer between dose adjustments.

Precautions

This medication can have side effects that affect muscles; therefore, if symptoms like muscle pain or weakness occur, notify your doctor immediately. Patients taking high doses of this medication are at increased risk for myopathy or rhabdomyolysis, so caution is necessary. This medication may affect liver function, so it should not be taken by patients with liver disease or abnormally high liver function test results. Women who are pregnant or may become pregnant, as well as nursing women, should not take this medication. The risk of muscle-related side effects may increase when this medication is taken with certain drugs, so consult your doctor or pharmacist if you are on other medications. Elderly patients, women, and those with kidney or thyroid dysfunction should exercise particular caution when taking this medication. Regular liver function tests and muscle-related tests are recommended, and if any abnormal symptoms occur, consult a healthcare provider immediately. This medication may interact with certain foods, such as grapefruit juice, so it is advisable to avoid grapefruit juice while taking it. It is not recommended for children or patients under the age of 10, and in children over 10 years of age, it should be taken according to a doctor's advice. In the event of overdose, contact a healthcare provider immediately for appropriate treatment. This medication should be stored in its original container and kept out of reach of children.

Side effects

  • myopathy
  • rhabdomyolysis
  • abdominal pain
  • weakness
  • constipation
  • diarrhea
  • dyspepsia
  • bloating
  • nausea
  • headache
Show 85 more
  • upper respiratory infection
  • edema
  • atrial fibrillation
  • gastritis
  • diabetes
  • myalgia
  • insomnia
  • dizziness
  • bronchitis
  • sinusitis
  • eczema
  • urinary tract infection
  • immune-mediated necrotizing myopathy
  • specific cranial nerve dysfunction
  • tremor
  • sensory abnormality
  • peripheral neuropathy
  • peripheral nerve paralysis
  • mental disorders
  • anxiety
  • sleep disorders
  • depression
  • cognitive impairment
  • myasthenia gravis
  • ocular myasthenia gravis
  • anaphylaxis
  • angioedema
  • lupus-like syndrome
  • polymyositis
  • dermatomyositis
  • vasculitis
  • purpura
  • thrombocytopenia
  • leukopenia
  • hemolytic anemia
  • positive antinuclear antibodies
  • increased erythrocyte sedimentation rate
  • eosinophilia
  • arthritis
  • arthralgia
  • urticaria
  • photosensitivity
  • fever
  • chills
  • flushing
  • malaise
  • dyspnea
  • toxic epidermal necrolysis
  • mucocutaneous syndrome
  • erythema multiforme
  • pancreatitis
  • hepatitis
  • liver failure
  • obstructive jaundice
  • fatty liver change
  • liver cirrhosis
  • fulminant liver necrosis
  • liver cancer
  • anorexia
  • vomiting
  • alopecia
  • pruritus
  • skin changes
  • lichenoid drug eruption
  • gynecomastia
  • decreased libido
  • sexual dysfunction
  • cataract progression
  • ocular muscle paralysis
  • anemia
  • elevated aminotransferases
  • elevated ALP
  • elevated γ-GTP
  • elevated bilirubin levels
  • thyroid dysfunction
  • elevated serum creatine kinase
  • abnormal liver function tests
  • increased HbA1c
  • increased fasting blood glucose levels
  • sensory impairment of the limbs
  • paresthesia
  • cold sensation
  • decreased muscle strength
  • thrombocytopenia
  • interstitial lung disease

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to protect it from air and moisture. Furthermore, to maintain the medication's effectiveness, it is important to store it at room temperature between 1 degree and 30 degrees.

Appearance and packaging

Appearance

Brownish yellow oval film-coated tablet

Package unit

(Domestic) 30 tablets/bottle, 100 tablets/bottle (Export) 30 tablets (10 tablets x 3 PTP)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.